These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

813 related items for PubMed ID: 19117687

  • 1. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
    Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A.
    Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
    [Abstract] [Full Text] [Related]

  • 2. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.
    J Clin Oncol; 2009 Dec 10; 27(35):5924-30. PubMed ID: 19884556
    [Abstract] [Full Text] [Related]

  • 3. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
    Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A.
    Cancer Treat Rev; 2010 Nov 10; 36 Suppl 3():S56-61. PubMed ID: 21129611
    [Abstract] [Full Text] [Related]

  • 4. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.
    Acta Oncol; 2014 Jul 10; 53(7):852-64. PubMed ID: 24666267
    [Abstract] [Full Text] [Related]

  • 5. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.
    J Clin Oncol; 2008 Dec 10; 26(35):5705-12. PubMed ID: 19001320
    [Abstract] [Full Text] [Related]

  • 6. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A.
    J Clin Oncol; 2009 Jun 01; 27(16):2622-9. PubMed ID: 19398573
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
    Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG.
    Cancer Chemother Pharmacol; 2011 Oct 01; 68(4):1045-55. PubMed ID: 21340604
    [Abstract] [Full Text] [Related]

  • 9. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P, Berkovcová J.
    Cesk Patol; 2011 Oct 01; 47(4):154-8. PubMed ID: 22145213
    [Abstract] [Full Text] [Related]

  • 10. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martinez-Fernandez A, Martinez-Aviles L, Cañadas I, Dalmases A, Moragon E, Lema L, Serrano S, Rovira A, Rojo F, Bellmunt J, Albanell J.
    Br J Cancer; 2010 Mar 30; 102(7):1137-44. PubMed ID: 20234366
    [Abstract] [Full Text] [Related]

  • 11. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.
    Genet Med; 2013 Jul 30; 15(7):517-27. PubMed ID: 23429431
    [Abstract] [Full Text] [Related]

  • 12. [Predictive factors of response to anti-EGFR treatments in colorectal cancer].
    Lièvre A, Laurent-Puig P.
    Bull Cancer; 2008 Jan 30; 95(1):133-40. PubMed ID: 18230579
    [Abstract] [Full Text] [Related]

  • 13. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
    Inno A, Di Salvatore M, Cenci T, Martini M, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C.
    Clin Colorectal Cancer; 2011 Dec 30; 10(4):325-32. PubMed ID: 21729677
    [Abstract] [Full Text] [Related]

  • 14. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
    Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL.
    Int J Cancer; 2013 Oct 15; 133(8):1914-25. PubMed ID: 23494461
    [Abstract] [Full Text] [Related]

  • 15. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 15; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 16. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    Bardelli A, Siena S.
    J Clin Oncol; 2010 Mar 01; 28(7):1254-61. PubMed ID: 20100961
    [Abstract] [Full Text] [Related]

  • 17. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.
    Russo A, Rizzo S, Bronte G, Silvestris N, Colucci G, Gebbia N, Bazan V, Fulfaro F.
    Oncology; 2009 Mar 01; 77 Suppl 1():57-68. PubMed ID: 20130433
    [Abstract] [Full Text] [Related]

  • 18. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A, Graziano F, Canestrari E, Magnani M.
    Curr Cancer Drug Targets; 2010 Feb 01; 10(1):68-79. PubMed ID: 20088793
    [Abstract] [Full Text] [Related]

  • 19. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.
    Blank PR, Moch H, Szucs TD, Schwenkglenks M.
    Clin Cancer Res; 2011 Oct 01; 17(19):6338-46. PubMed ID: 21807639
    [Abstract] [Full Text] [Related]

  • 20. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.
    Lin JK, Lin AJ, Lin CC, Lan YT, Yang SH, Li AF, Chang SC.
    J Surg Oncol; 2011 Nov 01; 104(6):661-6. PubMed ID: 21671463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.